Molecular mechanisms of pituitary adenoma senescence

Frontiers of Hormone Research

Volumn 38, Issue , 2010, Pages 7-14

  Chesnokova, Vera ^a   Zonis, Svetlana ^a   Ben Shlomo, Anat ^a   Wawrowsky, Kolja ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; BENIGN TUMOR; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DNA DAMAGE; GENETIC PREDISPOSITION; GENETIC TRANSFORMATION; HUMAN; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SENESCENCE;

ADENOMA; ANIMALS; CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; NEOPLASM PROTEINS; PITUITARY NEOPLASMS;

EID: 84926128831     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000318489     Document Type: Review

References (43)

1. Asa SL, Ezzat S: The pathogenesis of pituitary tumors. Annu Rev Pathol 2009;4:97-126.
2. Lania AG, Mantovani G, Spada A: Mechanisms of disease: Mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab 2006;2:681-693.
3. Melmed S: Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618.
4. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
5. Viacava P, Gasperi M, Acerbi G, et al: Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 2003;26:23-28.
6. Hayflick L, Perkins F, Stevenson RE: Human Diploid Cell Strains. Science 1964;143:976.
7. Sharpless NE, DePinho RA: Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004;113:160-168.
8. Serrano M, Blasco MA: Putting the stress on senescence. Curr Opin Cell Biol 2001;13:748-753.
9. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
10. Collado M, Gil J, Efeyan A, et al: Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.
11. Braig M, Lee S, Loddenkemper C, et al: Oncogene-induced senescence as an initial barrier in lym-phoma development. Nature 2005;436:660-665.
12. Michaloglou C, Vredeveld LC, Soengas MS, Deno-yelle C, Kuilman T, van der Horst CM, Majoor DM, Shay J W, Mooi WJ, Peeper DS: BRAFE600-asso-ciated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-724.
13. Ohtani N, Mann DJ, Hara E: Cellular senescence: its role in tumor suppression and aging. Cancer Sci 2009;100:792-797.
14. Campisi J: Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-S31.
15. Campisi J: Suppressing cancer: the importance of being senescent. Science 2005;309:886-887.
16. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
17. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-346.
18. Palmero I, Pantoja C, Serrano M: p19ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125-126.
19. Kiyokawa H, Koff A: Roles of cyclin-dependent kinase inhibitors: lessons from knockout mice. Curr Top Microbiol Immunol 1998;227:105-120.
20. Mooi WJ, Peeper DS: Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006;355:1037-1046.
21. Kuilman T, Peeper DS: Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009;9:81-94.
22. Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997;11:433-441.
23. Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-422.
24. Yu R, Heaney AP, Lu W, Chen J, Melmed S: Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 2000;275:36502-36505.
25. Yu R, Lu W, Chen J, McCabe CJ, Melmed S: Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 2003;144:4991-4998.
26. Vlotides G, Eigler T, Melmed S: Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007;28:165-186.
27. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
28. Ishikawa H, Heaney A P, Yu R, Horwitz GA, Melmed S: Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 2001;86:867-874.
29. Heaney A P, Horwitz GA, Wang Z, Singson R, Melmed S: Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma patho-genesis. Nat Med 1999;5:1317-1321.
30. Hamid T, Kakar SS: PTTG/securin activates expression of p53 and modulates its function. Mol Cancer 2004;3:18.
31. McCabe CJ, Khaira JS, Boelaert K, Heaney A P, Tan-nahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, et al: Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 2003;58:141-150.
32. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, Wawrowsky K, Melmed S: Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 2005;19:1383-1391.
33. Donangelo I, Melmed S: Implication of pituitary tropic status on tumor development. Front Horm Res 2006;35:1-8.
34. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S: Pituitary hypoplasia in Pttg-/-mice is protective for Rb+/-pituitary tumorigenesis. Mol Endocrinol 2005;19:2371-2379.
35. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 2007;67:10564-10572.
36. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S: p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 2008;105:17498-17503.
37. Chesnokova V, Melmed S: Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res 2009;71(suppl 2):82-87.
38. Lazzerini Denchi E, Attwooll C, Pasini D, Helin K: Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005;25:2660-2672.
39. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. Cell 2007;130:223-233.
40. Arzt E: gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways. J Clin Invest 2001;108:1729-1733.
41. Arzt E, Pereda MP, Castro C P, Pagotto U, Renner U, Stalla GK: Pathophysiological role of the cytokine network in the anterior pituitary gland. Front Neuroendocrinol 1999;20:71-95.
42. Arzt E, Chesnokova V, Stalla GK, Melmed S: Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle 2009;8:677-678.
43. Cichowski K, Hahn WC: Unexpected pieces to the senescence puzzle. Cell 2008;133:958-961.